Graham Reeve - May 10, 2024 Form 4 Insider Report for U S PHYSICAL THERAPY INC /NV (USPH)

Role: COO
Signature: /s/ Graham Reeve
Stock symbol: USPH
Transactions as of: May 10, 2024
Transactions value $: -$181,813
Form type: 4
Date filed: 5/14/2024, 06:15 PM
Previous filing: Mar 5, 2024
Next filing: Aug 21, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	USPH	Common Stock	Sale	-$182K	-1.72K	-19.83%	$105.46	6.97K	May 10, 2024	Reeve Trust	F1
holding	USPH	Common Stock						16.5K	May 10, 2024	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported ($105.46) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $105.44 to $105.50 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2	Includes 16,468 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,792 shares on July 1, 2024, and October 1, 2024; 1,793 shares on January 1, 2025, 1,442 shares on April 1, 2025, July 1, 2025, October 1, 2025; 1,459 shares on January 1, 2026; 818 shares on April 1, 2026, July 1, 2026, October 1, 2026; 827 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027 and 507 shares on Janaury 2028, if he is a director of the Company on those dates.

Content

The price reported ($105.46) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $105.44 to $105.50 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Includes 16,468 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,792 shares on July 1, 2024, and October 1, 2024; 1,793 shares on January 1, 2025, 1,442 shares on April 1, 2025, July 1, 2025, October 1, 2025; 1,459 shares on January 1, 2026; 818 shares on April 1, 2026, July 1, 2026, October 1, 2026; 827 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027 and 507 shares on Janaury 2028, if he is a director of the Company on those dates.